Reference : Treatment of acute hepatitis C with interferon alpha-2b: early initiation of treatment i...
Scientific journals : Article
Human health sciences : Gastroenterology & hepatology
Human health sciences : Pharmacy, pharmacology & toxicology
http://hdl.handle.net/2268/15955
Treatment of acute hepatitis C with interferon alpha-2b: early initiation of treatment is the most effective predictive factor of sustained viral response
English
Delwaide, Jean mailto [Université de Liège - ULg > > Gastro-Entérologie-Hépatologie >]
Bourgeois, N. [> > > >]
Gerard, Christiane mailto [Centre Hospitalier Universitaire de Liège - CHU > > Hématologie biologique et immuno hématologie >]
De Maeght, S. [> > > >]
Mokaddem, F. [> > > >]
Wain, E. [> > > >]
Bastens, B. [> > > >]
Fevery, J. [> > > >]
Gehenot, M. [> > > >]
Le Moine, O. [> > > >]
Martinet, J. P. [> > > >]
Robaeys, G. [> > > >]
Servais, B. [> > > >]
Van Gossum, M. [> > > >]
Van Vlierberghe, H. [> > > >]
1-Jul-2004
Alimentary Pharmacology & Therapeutics
Blackwell Publishing Ltd
20
1
15-22
Yes (verified by ORBi)
International
0269-2813
Oxford
[en] AIM: To evaluate the efficacy of early interferon alpha-2b in non-post-transfusion acute hepatitis C virus: a prospective study with historical comparison. PATIENTS: Group A: 28 patients prospectively treated for acute hepatitis C virus with daily regimen of interferon 5 million units for 2 months. Group B: historical series of 16 patients with untreated acute hepatitis C virus. RESULTS: There was no significant difference between the two groups with regard to gender, age, icterus, alanine aminotransferase, or genotypes. In group B, hepatitis spontaneously resolved in three of 16 (19%) patients (follow-up 1-7 years). In group A, 21 of 25 patients became sustained viral responders (75%; P = 0.0003 vs. group B). Factors include not predictive of sustained viral response: age, gender, sources of infection, presence of icterus, alanine aminotransferase peak, bilirubin peak, incubation period, presence of hepatitis C virus antibodies at presentation, or genotypes. The time from presentation to the start of therapy was, however, significantly shorter in sustained viral responders (43 +/- 31 days) than in relapsers or non-responders (88 +/- 52 days) (P = 0.016). CONCLUSIONS: Early treatment of acute hepatitis C virus with interferon prevents chronicity. A short waiting time from presentation to treatment appears as the most relevant predictive factor for sustained response.
http://hdl.handle.net/2268/15955
10.1111/j.1365-2036.2004.02023.x

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
delwaide treatment 2004.pdfNo commentaryPublisher postprint79.25 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.